Panel Discussion: Evaluating the Cutting-Edge Innovation & Performance Driving ADC Differentiation & Progression To Earlier Line Patient Therapies

7:45 am - Tuesday 24th February 2026

  • Understanding the 2026 ADC landscape and how the bar has been raised to develop and deliver differentiated ADCs with meaningful patient impact
  • Assessing the need for novel ADC chemistry innovation: What is showing the most promise across novel payloads and conjugation technologies?
  • Discussing the potential of novel ADC biology approaches across bispecific targeting and antibody engineering to unlock next generation ADC therapies
  • Highlighting methods to best pursue ADC clinical differentiation across patient selections methods, combination strategies, and well executed clinical design

Speakers:

Chief Scientific Officer
Iksuda Therapeutics
Executive Director & Head, Tumour Targeted Delivery Bioscience, Oncology R&D
AstraZeneca
VP, Research & Head, R&D Technology and Innovation
Amgen
Partner & Co-Founder
Genesis BioCapital
Chief Scientific Officer
Sutro Biopharma
Senior Vice President & Head, Biotech Unit & Development Innovation
BeOne Medicines